125 related articles for article (PubMed ID: 2322990)
1. Flavone acetic acid distribution in human malignant tumors.
Damia G; Freschi A; Sorio R; Braida A; Caruso G; Quaia M; Monfardini S; D'Incalci M
Cancer Chemother Pharmacol; 1990; 26(1):67-70. PubMed ID: 2322990
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice.
Cummings J; Double JA; Bibby MC; Farmer P; Evans S; Kerr DJ; Kaye SB; Smyth JF
Cancer Res; 1989 Jul; 49(13):3587-93. PubMed ID: 2731178
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice.
Chabot GG; Bissery MC; Corbett TH; Rutkowski K; Baker LH
Cancer Chemother Pharmacol; 1989; 24(1):15-22. PubMed ID: 2597279
[TBL] [Abstract][Full Text] [Related]
4. Tumour concentrations of flavone acetic acid (FAA) in human melanoma: comparison with mouse data.
Maughan TS; Ward R; Dennis I; Honess DJ; Workman P; Bleehen NM
Br J Cancer; 1992 Sep; 66(3):579-82. PubMed ID: 1520597
[TBL] [Abstract][Full Text] [Related]
5. A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid.
Olver IN; Webster LK; Bishop JF; Stokes KH
Cancer Chemother Pharmacol; 1992; 29(5):354-60. PubMed ID: 1551173
[TBL] [Abstract][Full Text] [Related]
6. Tumour necrosis factor-alpha plasma levels after flavone acetic acid administration in man and mouse.
Chabot GG; Branellec D; Sassi A; Armand JP; Gouyette A; Chouaib S
Eur J Cancer; 1993; 29A(5):729-33. PubMed ID: 8471332
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of flavone acetic acid (NSC 347512, LM975) in patients with pediatric malignant solid tumors.
Pratt CB; Relling MV; Meyer WH; Douglass EC; Kellie SJ; Avery L
Am J Clin Oncol; 1991 Dec; 14(6):483-6. PubMed ID: 1957836
[TBL] [Abstract][Full Text] [Related]
8. Saturable elimination and saturable protein binding account for flavone acetic acid pharmacokinetics.
Relling MV; Evans RR; Groom S; Crom WR; Pratt CB
J Pharmacokinet Biopharm; 1993 Dec; 21(6):639-51. PubMed ID: 8138891
[TBL] [Abstract][Full Text] [Related]
9. Flavone acetic acid pharmacokinetics in nude mice.
Damia G; Garofalo A; Rossi C; Giavazzi R; D'Incalci M
Anticancer Res; 1990; 10(2A):437-9. PubMed ID: 2346316
[TBL] [Abstract][Full Text] [Related]
10. Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. IV: Pharmacokinetics and toxicity of flavone acetic acid and its metabolites.
Stratford MR; Rustin GJ; Dennis MF; Watfa RR; Howells N; O'Reilly SM
Br J Cancer; 1993 Jun; 67(6):1351-5. PubMed ID: 8512820
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent pharmacokinetics of flavone acetic acid in mice.
Damia G; Zanette ML; Rossi C; Mandelli R; Ferrari A; D'Incalci M
Cancer Chemother Pharmacol; 1988; 22(1):47-50. PubMed ID: 3396145
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization.
de Forni M; Chabot GG; Armand JP; Gouyette A; Klink-Alak M; Recondo G
Cancer Chemother Pharmacol; 1995; 35(3):219-24. PubMed ID: 7805180
[TBL] [Abstract][Full Text] [Related]
13. Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice.
McKeage MJ; Kestell P; Denny WA; Baguley BC
Cancer Chemother Pharmacol; 1991; 28(6):409-13. PubMed ID: 1934244
[TBL] [Abstract][Full Text] [Related]
14. The relationship between tissue levels of flavone acetic acid (NSC 347512) and site dependent anti-tumour activity in murine colon tumours.
Bibby MC; Phillips RM; Double JA
Br J Cancer; 1991 Apr; 63(4):541-5. PubMed ID: 2021538
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of flavone acetic acid.
Kerr DJ; Kaye SB; Cassidy J; Bradley C; Rankin EM; Adams L; Setanoians A; Young T; Forrest G; Soukop M
Cancer Res; 1987 Dec; 47(24 Pt 1):6776-81. PubMed ID: 3677106
[TBL] [Abstract][Full Text] [Related]
16. Flavone acetic acid (LM-975; NSC-347512) activation to cytotoxic species in vivo and in vitro.
Chabot GG; Bissery MC; Gouyette A
Cancer Chemother Pharmacol; 1989; 24(5):273-6. PubMed ID: 2758556
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumour activity of flavone acetic acid (NSC 347512) in mice--influence of immune status.
Bibby MC; Phillips RM; Double JA; Pratesi G
Br J Cancer; 1991 Jan; 63(1):57-62. PubMed ID: 1989665
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma.
Sun JR; Brown JM
Cancer Res; 1989 Oct; 49(20):5664-70. PubMed ID: 2790784
[TBL] [Abstract][Full Text] [Related]
19. Flavone acetic acid increases the antitumor effect of hyperthermia in mice.
Sakaguchi Y; Maehara Y; Baba H; Kusumoto T; Sugimachi K; Newman RA
Cancer Res; 1992 Jun; 52(12):3306-9. PubMed ID: 1596889
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
